Gene · 375790
AGRN: agrin
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. AGRN: agrin. Genes, record 375790. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/375790
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O00468 | Agrin | 2,068 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents15
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026090543 A | 2026-06-02 | 432 | O00468 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 31843 | O00468 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 349 | O00468 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5435 | O00468 | Espacenet |
| EP 4606428 A2 | 2025-08-27 | 3 | O00468 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 349 | O00468 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5435 | O00468 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 31843 | O00468 | Espacenet |
| EP 4400164 A2 | 2024-07-17 | 4 | O00468 | Espacenet |
| JP 2024523001 A | 2024-06-25 | 705 | O00468 | Espacenet |
1 to 10 of 15
See all 15 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,943
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | AGRN papers | Newest fiscal year |
|---|---|---|---|
| R01AI114780 | Mechanisms of autoimmunity in myasthenia gravis | 10 | 2025 |
| U54NS115054 | Rare Disease Network for Myasthenia Gravis | 8 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 7 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 6 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 5 | 2025 |
| P30EY003790 | Core Grant for Vision Research | 4 | 2025 |
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 4 | 2025 |
| P30AG028740 | University of Florida Older Americans Independence Center (OAIC) | 3 | 2025 |
1 to 10 of 1,943Source NIH's project files
See all 1,943 nih grantsPapers3,257
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Assay-specific reference intervals and evaluation of key preanalytical factors for C-terminal agrin fragment measured using the Abcam ab216945 ELISA. | Clin Chim Acta | 2027 | 42648525 | PubTator, text mining | PubMed |
| Ramadan fasting influences respiratory sarcopenia and plasma markers of neuromuscular junction health in older adults. | Eur J Appl Physiol | 2026 | 42806069 | PubTator, text mining | PubMed |
| Crk/Crk-L-mediated Rapgef1 recruitment couples MuSK signaling to AChR anchoring at the neuromuscular junction. | Cell Chem Biol | 2026 | 42772281 | PubTator, text mining | PubMed |
| Ultrasound-Derived Quadriceps Muscle Measurements Are Independently Associated With Physical Frailty in Patients Undergoing Hemodialysis. | J Ren Nutr | 2026 | 42767388 | PubTator, text mining | PubMed |
| Circulating Serum AGRN and ADAMTS8 With Related Candidates as Potential Biomarkers for Carotid Plaque Presence and Vulnerability. | CNS Neurosci Ther | 2026 | 42747227 | PubTator, text mining | PubMed |
| AGRN activates GPX4 via the Wnt/beta-catenin signaling pathway to suppress ferroptosis in cervical cancer cells. | Brief Funct Genomics | 2026 | 42742282 | PubTator, text mining | PubMed |
| Protein mediators of chronic kidney disease in Type 2 diabetes: A mendelian randomization study. | PLoS Med | 2026 | 42726788 | PubTator, text mining | PubMed |
| NMJ-associated transcriptomic remodeling correlates with disease severity in juvenile dermatomyositis. | Inflamm Res | 2026 | 42700229 | PubTator, text mining | PubMed |
| Targeting RhoA/ROCK Signaling to Modulate Extracellular Matrix Remodeling in Corneal Endothelial Dystrophies. | Invest Ophthalmol Vis Sci | 2026 | 42593179 | PubTator, text mining | PubMed |
| MuSK myasthenia gravis: from antigen-antibody to clinical translation. | Front Immunol | 2026 | 42582756 | PubTator, text mining | PubMed |
1 to 10 of 3,257
See all 3,257 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/375790
GET https://conductscience.org/api/genes/v1/375790/patents